Abeta amyloid imaging in neurodegenerative disorders with a novel 18F radiotracer

使用新型 18F 放射性示踪剂对神经退行性疾病进行 Abeta 淀粉样蛋白成像

• 批准号: nhmrc : 509166
• 负责人: A/Pr Victor Villemagne
• 金额: $ 72.3万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/abeta-amyloid-imaging-18f-radiotracer/99475
• 关键词: Abeta; amyloid; imaging; neurodegenerative; disorders

Alzheimer's disease is the most common age-related neurodegenerative disease, and the most common cause of dementia. It is estimated that 212,000 Australians suffer from dementia and this will rise to approximately 730,000 by 2050. Currently there are no definitive diagnostic methods for AD. The research proposed in this application describes the evaluation of a new imaging radiotracer that would be suitable for widespread non-invasive diagnosis of AD.

阿尔茨海默病是最常见的与年龄相关的神经退行性疾病，也是痴呆症的最常见原因。据估计，有21.2万澳大利亚人患有痴呆症，到2050年，这一数字将上升到约73万。目前对阿尔茨海默病没有明确的诊断方法。本申请中提出的研究描述了一种新的成像放射性示踪剂的评估，该示踪剂将适用于广泛的AD非侵入性诊断。